The dosage of Rezvilutamide Tablets must be administered in strict accordance with medical advice. The usual recommended dose is 300 mg (3 tablets) once daily. The specific dosage regimen shall be adjusted according to the patient’s condition, tolerability and clinical evaluation by the physician.
As a prescription drug, the dosage must not be increased, decreased or discontinued without authorization, so as to avoid compromising efficacy or increasing safety risks.
I. Standard Dosage Instructions
Routine dosage
In most cases, the physician will recommend oral administration of 300 mg (3 tablets of 100 mg strength) once daily. The tablets can be taken with or without food.
Individualized adjustment
For some patients with abnormal liver function, drug–drug interactions, or adverse reactions (e.g., fatigue, rash), the dosage may be adjusted to 200 mg (2 tablets) or temporarily discontinued after evaluation by a physician.
II. Administration Method
Dosing time
It is recommended to take the medicine at a fixed time every day to avoid missed doses.
If a dose is missed, take it as soon as possible on the same day.
If it is nearly time for the next dose, skip the missed dose; do not take a double dose.
Administration route
Swallow the tablet whole; do not chew or crush.
If blood glucose control or dietary restrictions are required, administration may be on an empty stomach or with meals, but a consistent daily routine should be maintained.
III. Precautions
Strictly follow medical advice
Rezvilutamide Tablets are indicated for the treatment of conditions including prostate cancer. The dosage is determined comprehensively based on tumor stage, treatment plan (e.g., combination with other agents), and the patient’s physical condition.
Regular follow‑up and monitoring
During treatment, regular rechecks of liver function, blood routine and other indicators are required. Any adverse reactions such as muscle pain or dysuria should be reported promptly to allow timely regimen adjustment.
Contraindications and drug interactions
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) should be avoided, as they may alter drug efficacy or increase toxicity. Inform your doctor of all concurrent medications in advance.
IV. Medical Guidance
Seek immediate medical attention if severe side effects (e.g., arrhythmia, dyspnea) occur or if the treatment effect is unsatisfactory.
Patients must not switch brands, adjust the treatment course, or discontinue the drug without authorization, to avoid disease progression or drug resistance.
